• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Commentary on: Abiraterone Plus Prednisolone in Metastatic, Castration-sensitive Prostate Cancer.

作者信息

Struss Werner J, Black Peter C

机构信息

Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.

出版信息

Urology. 2017 Nov;109:1-2. doi: 10.1016/j.urology.2017.07.032. Epub 2017 Aug 7.

DOI:10.1016/j.urology.2017.07.032
PMID:28797683
Abstract
摘要

相似文献

1
Commentary on: Abiraterone Plus Prednisolone in Metastatic, Castration-sensitive Prostate Cancer.关于“阿比特龙联合泼尼松用于转移性去势敏感性前列腺癌”的述评
Urology. 2017 Nov;109:1-2. doi: 10.1016/j.urology.2017.07.032. Epub 2017 Aug 7.
2
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.镭-223 联合醋酸阿比特龙和泼尼松或泼尼松龙治疗去势抵抗性前列腺癌和骨转移患者（ERA 223）：一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet Oncol. 2019 Mar;20(3):408-419. doi: 10.1016/S1470-2045(18)30860-X. Epub 2019 Feb 6.
3
A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study).醋酸阿比特龙在未经化疗的日本转移性去势抵抗性前列腺癌男性患者中的2期试验（JPN - 201研究）
Jpn J Clin Oncol. 2014 Dec;44(12):1216-26. doi: 10.1093/jjco/hyu149. Epub 2014 Oct 15.
4
Re: Prostate-Specific Antigen Decline after 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer.回复：醋酸阿比特龙治疗4周后前列腺特异性抗原下降情况及转移性去势抵抗性前列腺癌患者的总生存期
J Urol. 2016 Jul;196(1):103. doi: 10.1016/j.juro.2016.04.040. Epub 2016 Apr 14.
5
Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study.醋酸阿比特龙联合泼尼松治疗一线去势治疗失败的转移性去势抵抗性前列腺癌患者的疗效和安全性：一项单臂、4 期研究。
Jpn J Clin Oncol. 2021 Apr 1;51(4):544-551. doi: 10.1093/jjco/hyaa225.
6
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).醋酸阿比特龙在未接受过化疗的转移性去势抵抗性前列腺癌患者中的更新中期疗效分析及长期安全性（COU-AA-302）
Eur Urol. 2014 Nov;66(5):815-25. doi: 10.1016/j.eururo.2014.02.056. Epub 2014 Mar 6.
7
Comment on: "Modeling the Relationship between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer".关于《转移性去势抵抗性前列腺癌患者阿比特龙暴露与前列腺特异性抗原动力学之间的关系建模》的评论
Clin Pharmacokinet. 2017 Feb;56(2):211-212. doi: 10.1007/s40262-016-0468-2.
8
A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy.一项针对接受多西他赛化疗的日本转移性去势抵抗性前列腺癌男性患者的醋酸阿比特龙2期研究。
Jpn J Clin Oncol. 2014 Dec;44(12):1206-15. doi: 10.1093/jjco/hyu148. Epub 2014 Oct 1.
9
Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.醋酸阿比特龙联合泼尼松治疗转移性去势抵抗性前列腺癌患者后的雄激素信号靶向治疗的临床结局：COU-AA-302 的事后分析。
Eur Urol. 2017 Jul;72(1):10-13. doi: 10.1016/j.eururo.2017.03.007. Epub 2017 Mar 15.
10
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.阿比特龙联合泼尼松治疗转移性去势敏感性前列腺癌。
N Engl J Med. 2017 Jul 27;377(4):352-360. doi: 10.1056/NEJMoa1704174. Epub 2017 Jun 4.

引用本文的文献

1
Innovative Drug Modalities for the Treatment of Advanced Prostate Cancer.用于治疗晚期前列腺癌的创新药物模式
Diseases. 2024 May 2;12(5):87. doi: 10.3390/diseases12050087.